FASN up-regulation and its association with a poor prognosis holds true for other cancer types as well [107,108,109], making this a universal cancer feature and thus supporting its usefulness as a therapeutic target of ccRCC. The gene discussed is FASN; the disease is nonpapillary renal cell carcinoma.